PakistanTuberculosis profile
Population  2014 185 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 48 (11–110) 26 (6–61)
Mortality (HIV+TB only) 1.3 (0.76–1.9) 0.68 (0.41–1)
Prevalence  (includes HIV+TB) 630 (530–740) 341 (285–402)
Incidence  (includes HIV+TB) 500 (370–650) 270 (201–350)
Incidence (HIV+TB only) 6.4 (4.4–8.7) 3.4 (2.4–4.7)
         
Case detection, all forms (%) 62 (48–83)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.7 (2.5–5) 18 (13–23)
MDR-TB cases among notified pulmonary
TB cases
9 000 (6 100–12 000) 2 900 (2 100–3 700)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 122 537   7 420
Pulmonary, clinically diagnosed 120 350   426
Extrapulmonary 57 463   221
       
Total new and relapse 308 417    
Previously treated, excluding relapses 8 160    
Total cases notified 316 577    
Among 308 417 new and relapse cases:
27 245 (9%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 361 (<1%) 11 685 (72%) 20 143
Laboratory-confirmed RR-/MDR-TB cases     3 243
Patients started on MDR-TB treatment ***     2 662
TB/HIV 2014 Number (%)
TB patients with known HIV status 10 715 (3)
HIV-positive TB patients 90 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 90 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 90 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (93) 289 376
Previously treated cases, excluding relapse, registered in 2013 (80) 7 217
HIV-positive TB cases, all types, registered in 2013 (81) 37
RR-/MDR-TB cases started on second-line treatment in 2012 (71) 858
XDR-TB cases started on second-line treatment in 2012 (32) 41
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 42
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 50
% Funded domestically 17%
% Funded internationally 60%
% Unfunded 23%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-30 Data: www.who.int/tb/data